Tempus AI (NASDAQ:TEM) Price Target Raised to $85.00

Tempus AI (NASDAQ:TEM) had its price objective increased by HC Wainwright from $68.00 to $85.00 in a research report report published on Tuesday morning, MarketBeat Ratings reports. The firm currently has a buy rating on the stock.

Several other brokerages have also issued reports on TEM. BTIG Research lifted their target price on shares of Tempus AI from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday. The Goldman Sachs Group began coverage on shares of Tempus AI in a research note on Monday, September 21st. They issued a “neutral” rating and a $75.00 price target for the company. Cantor Fitzgerald began coverage on shares of Tempus AI in a report on Wednesday, September 2nd. They issued an “overweight” rating and a $80.00 price target on the stock. Piper Sandler upgraded shares of Tempus AI from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $56.00 to $76.00 in a research report on Tuesday, September 1st. Finally, Stifel Nicolaus lowered their price objective on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a research report on Monday, August 3rd. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $79.37.

Tempus AI Stock Performance

NASDAQ:TEM opened at $70.43 on Tuesday. The business’s 50-day moving average price is $71.21 and its two-hundred day moving average price is $57.20. Tempus AI has a twelve month low of $40.77 and a twelve month high of $89.09. The stock has a market cap of $12.71 billion, a P/E ratio of -66.44 and a beta of 3.61. The company has a quick ratio of 3.16, a current ratio of 2.61 and a debt-to-equity ratio of 2.70.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Monday, November 2nd. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.16. The company had revenue of $411.54 million during the quarter, compared to analyst estimates of $409.39 million. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. Tempus AI’s revenue was up 23.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. As a group, equities analysts predict that Tempus AI will post -1.45 EPS for the current fiscal year.

Insider Transactions at Tempus AI

In other news, EVP Andrew Polovin sold 22,148 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the transaction, the executive vice president directly owned 146,067 shares in the company, valued at approximately $7,246,383.87. This represents a 13.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James Rogers sold 26,313 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total value of $1,578,780.00. Following the transaction, the chief financial officer directly owned 106,024 shares in the company, valued at approximately $6,361,440. This represents a 19.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 1,237,227 shares of company stock valued at $85,388,983 over the last quarter. 24.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently made changes to their positions in TEM. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares during the period. Amova Asset Management Americas Inc. raised its holdings in Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after buying an additional 821,490 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in Tempus AI by 2,965.7% during the 3rd quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock valued at $41,233,000 after buying an additional 486,493 shares during the period. Eagle Health Investments LP purchased a new stake in Tempus AI during the 1st quarter valued at $11,588,000. Finally, Swiss National Bank boosted its position in Tempus AI by 0.3% during the 1st quarter. Swiss National Bank now owns 183,500 shares of the company’s stock valued at $8,298,000 after buying an additional 600 shares during the period. 24.22% of the stock is currently owned by institutional investors.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Cantor Fitzgerald maintained its Buy rating, while HC Wainwright and Robert W. Baird were also reported to see strong potential appreciation. These recommendations may support investor confidence. Cantor Fitzgerald maintains Buy rating HC Wainwright forecast Baird forecast
• Positive Sentiment: Recent results were stronger than expected: Tempus reported quarterly revenue of $411.5 million, up 23.1% year over year, and earnings per share of $0.07 versus analysts’ forecast for a loss. The beat provides a favorable business-performance backdrop. Tempus AI earnings beat
• Negative Sentiment: CEO Ryan Fukushima sold 80 shares and director David Epstein sold 370 shares at $74.29. Both trades were executed under pre-arranged Rule 10b5-1 plans, and the small sales leave their substantial holdings largely intact, tempering the potential concern. Director stock sale disclosure

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.